[Pamidronate in treatment of pain caused by bone metastasis].
OBJECTIVE
Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis. This study was to observe curative effects, and side effects of different dosages of pamidronate on pain induced by bone metastasis.


METHODS
Ninety patients with metastatic bone tumor were divided into 2 groups randomly. In group A, 120 mg pamidronate was given by intravenous infusion in 3 days (60 mg day(1), 30 mg day(2-3)); in group B, 90 mg pamidronate was given by intravenous infusion in 3 days (30 mg day(1-3)), repeated every 4 weeks.


RESULTS
The notable effect, effect, and no effect were observed in 20, 23, and 2 patients of group A, and 16, 20, and 9 patients of group B, respectively. Total effective rate in group A was 95.6%(43/45) , in group B was 80.0% (36/45) (P< 0.05). Curative rate within 1 course of treatment in group A was 88.9% (40/45), in group B was 57.8% (26/45) (P< 0.01). Curative rate within 1 week in group A was 80% (36/45) , in group B was 57.8% (26/45) (P< 0.05). Side effects were observed in 3 patients (6.7%).


CONCLUSIONS
Pamidronate has good curative effects in treating pain induced by bone metastasis. Efficacy of 120 mg pamidronate is better than 90 mg pamidronate.
Wang
Di-Jin
DJ
Department of Medical Oncology, Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, 330029, P.R.China. wangdijin@hotmail.com
Liu
Hui-Qun
HQ
Ren
Jian
J
Chen
Ying-Lan
YL
Zhan
Qin-Yuan
QY
Cai
Yun
Y
Liu
Min-Zhi
MZ
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D000077268:Pamidronate; D013274:Stomach Neoplasms / Q000473:pathology
D004164:Diphosphonates; D000077268:Pamidronate